Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study
    Meeting Abstract

    Dean, A.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Colombo, N.; Weberpals, J.; Clamp, A. R.; Scambia, G.; Leary, A.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib + dostarlimab in patients with platinum-resistant ovarian cancer
    Meeting Abstract

    Randall, L. M.; O'Malley, D. M.; Monk, B. J.; Coleman, R. L.; O'Cearbhaill, R. E.; Gaillard, S.; Adams, S.; Cappuccini, F.; Huang, M.; Chon, H. S.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)
    Meeting Abstract

    Cohen, E. E.; Ferris, R. L.; Psyrri, A.; Haddad, R.; Tahara, M.; Bourhis, J.; Harrington, K. J.; Chang, P. M. H.; Lin, J. C.; Razaq, M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): Extended follow-up from CheckMate 032
    Meeting Abstract

    Sharma, P.; Siefker-Radtke, A. O.; de Braud, F.; Basso, U.; Calvo, E.; Bono, P.; Morse, M.; Ascierto, P. A.; Lopez-Martin, J.; Brossart, P.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1
    Meeting Abstract

    Banerjee, S.; Moore, K. N.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Efficacy and safety of niraparib in older patients (pts) with advanced ovarian cancer (OC): Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
    Meeting Abstract

    Valabrega, G.; Pothuri, B.; Oaknin, A.; Graybill, W.; Sánchez, A. B.; McCormick, C.; Baurain, J. F.; Hoskins, P.; Denys, H.; O'Cearbhaill, R. E.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Veliparib with carboplatin and paclitaxel in frontline high-grade serous ovarian cancer (HGSOC): Efficacy and safety of paclitaxel weekly and every 3 weeks in the VELIA study
    Meeting Abstract

    Okamoto, A.; Fleming, G.; Bookman, M.; Brady, M. F.; Swisher, E. M.; Steffensen, K. D.; Cloven, N. G.; Enomoto, T.; O'Malley, D. M.; Van Le, L.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Association between gene expression signatures (sigs) and pembrolizumab (pembro) efficacy in patients (pts) with advanced urothelial cancer (UC)
    Meeting Abstract

    Grivas, P.; Balar, A. V.; Vuky, J.; de Wit, R.; Vogelzang, N. J.; Choueiri, T. K.; Bajorin, D.; Castellano Gauna, D.; Gerritsen, W.; Gurney, H.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors
    Meeting Abstract

    O'Donnell, P.; Galsky, M. D.; Rosenberg, J. E.; Petrylak, D. P.; Balar, A. V.; McGregor, B. A.; Heath, E.; Yu, E. Y.; Quinn, D. I.; Hahn, N. M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Association of TMB with efficacy of pembrolizumab (pembro) in patients (pts) with advanced urothelial cancer (UC): Results from KEYNOTE-045 and KEYNOTE-052
    Meeting Abstract

    Bellmunt, J.; de Wit, R.; Fradet, Y.; Climent, M. A.; Petrylak, D. P.; Lee, J. L.; Fong, L.; Necchi, A.; Sternberg, C. N.; Grivas, P.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save